Article

Duke Macular Translocation Study group reports recurrence rates

There is a low rate of recurrent choroidal neovascularization (CNV) over 2 years in eyes that undergo macular translocation surgery with 360-degree peripheral retinectomy (MT-360) for exudative age-related macular degeneration, said Claxton A Baer, MD.

May 4

- Fort Lauderdale, FL - There is a low rate of recurrent choroidal neovascularization (CNV) over 2 years in eyes that undergo macular translocation surgery with 360-degree peripheral retinectomy (MT-360) for exudative age-related macular degeneration, said Claxton A Baer, MD.

He presented data from a series of 64 eyes of 64 participants in the Duke Macular Translocation study. That prospective, noncomparative trial enrolled second eyes of patients with neovascular age-related macular degeneration who were ineligible for or failed nonsurgical treatment.

Among 56 eyes seen at 2 years, 14 (25%) had developed recurrent CNV. No eyes developed geographic atrophy. Most cases of recurrence occurred within the first 9 months after surgery, only 2 patients developed recurrence after 1 year, and there were no new recurrences between 18 and 24 months. Thirteen of the 14 recurrences occurred from the old CNV bed and all crossed the margin of the old CNV bed.

Median visual acuity for the 14 eyes with recurrent CNV was 20/200 versus 20/80 for those without recurrence.

"We recommend close surveillance for recurrence in the first year after this surgery with special attention to the foveal side of the CNV bed as early recognition and new methods of treatment for CNV may prevent vision loss in this subgroup and improve overall outcomes," Dr. Baer said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.